Armata Pharmaceuticals, Inc. (ARMP) Stock Grade

About Armata Pharmaceuticals, Inc.'s fundamentals

Armata Pharmaceuticals is a small-cap biotechnology company with a market capitalization of $138.8 million that is currently unprofitable, reporting a net loss in its latest annual statement and a severe net margin of -3544.0%. The company experienced a revenue decline of 5.2% year-over-year, indicating contracting sales during the period. With no dividend yield and the absence of a traditional P/E ratio due to its negative earnings, the company is in a development or restructuring phase typical of early-stage biotech firms. The unusually high return on equity figure should be interpreted cautiously given the company's loss-making status and may not be indicative of sustainable shareholder value creation.